Our ever increasing knowledge of genetics is radically changing disciplines in science and medicine. Significantly, the study of gene expression and protein synthesis within both healthy and abnormal cells has advanced understanding of the mechanism of disease at the molecular level. The future treatment of certain diseases may benefit from new classes of nucleic acid based drugs which are currently undergoing development and trialling. Concurrently, assays are being formulated to predict, diagnose and monitor medical conditions. This more detailed patient analysis brings the option of moving away from traditional, textbook treatments and tailoring therapies to the individual, the field of personalised medicine. Current polynucleotide analysis platforms allow testing for genomic mutations and quantification of gene expression on a massively multiplexed scale with some arrays able to identify more than a million unique target sequences in a single assay. However much development is required to take this analysis technology from laboratory based applications to the bedside. Reductions in assay costs and analysis time are particular concerns. The 4G research group, based at the University of Southampton has developed novel encoded microparticle technology, allowing individual particles to be identified in a mixture. The work herein documents the adaption of this technology for the multiplexed analysis of DNA samples in the form of a suspension/hybridisation assay, a design which may offer advantages over current analysis technologies including reduced assay time and increased array flexibility.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:548275 |
| Date | January 2011 |
| Creators | Broder, Graham Richard |
| Contributors | Roach, Peter |
| Publisher | University of Southampton |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
| Source | https://eprints.soton.ac.uk/300024/ |
Page generated in 0.0019 seconds